UK Early Inflammatory Arthritis Audit of 20,060 RA pts (~12k on MTX; 5K csDMARD; ~2.5K no DMARD). Serious infections (SIE) hosp rate was 3.19/100PY, death 0.1/100PY. SIE risk incr w/ age, smoking, Hi DAS28 & HAQ. 1 unit DAS28, SI risk increased by 8% https://t.co/OrNh8oYE3y https://t.co/DqbeibNMbp

FDA issued a drug safety warning linking thiopurine (AZA, 6MP) use in pregnancy & a rare risk of intrahepatic cholestasis of pregnancy (ICP). ICP has been reported in pts w/ CD, UC, or SLE; however thiopurines are not FDA approved for these Dx https://t.co/XKoUdy4sAR https://t.co/DSU9z0v7CZ

British Society for Rheumatology (BSR) presented (at the 2024 annual BSR meeting) new guidelines for the management of Behçet's disease - how to manage skin lesions, mouth ulcers, genital ulcers, serious eye, CNS & vascular involvement https://t.co/d0bjKuubym https://t.co/lqoTeTGqZ7

Spondyloarthritis Faculty Panel Q&A Spondyloarthritis Faculty Panel Q&A - featuring Drs. Eric Ruderman, Lihi Eder, and Lianne Gensler; moderated by Dr. Artie Kavanaugh https://t.co/6RFkyO72e1 https://t.co/CJ174sETFv

Future Therapy of Axial Spondyloarthritis https://t.co/wjrlkuu0ds https://t.co/jQ12eTpT2l

Predicting Infection in Lupus Nephritis Machine learning (ML) models were applied to 3 cohorts of lupus nephritis (LN) patients and established algorithms to predict co-infection in LN. https://t.co/BnV7jVfqj1 https://t.co/LYQd6w1DvD

Our final TNR for the month of April will take place on 4/30 at 6:30pm ET. Mastering SLE Rethinking Pre-Clinical Disease in Lupus - David Karp, MD Biology and Rx of Lupus Flares - Michelle Kahlenberg, MD Current/Future Biomarkers in SLE - Andrea Fava, MD https://t.co/j05QmWg17f https://t.co/jDvP0iTS8T

Predicting CKD Outcomes in Lupus Nephritis An observational cohort study suggests that proteinuria levels in lupus nephritis (LN) patients did not predict their histologic class. https://t.co/UHNqj6WTXn https://t.co/IOc0Gv21FM

In biologic-naïve active PsA pts Rx w/ guselkumab & achieving enthesitis (ER) or dactylitis resolution (DR), had better PRO outcomes. GUS - ER or DR was assoc w/ minimal pain (p < 0.001), normalized HAQ-DI (p < 0.001), , better FACIT-Fatigue responses https://t.co/HymI7CBfXh https://t.co/dYk9qXdVpt

In 530 #GCA pts, relapses seen in 46%; but severe relapse (ischemi/aortic events) in 3%. Severe GCA relapse pts more likely to be younger at Dx(P=0.02), w/ more limb claudication(< 0.0001), fewer GCA-related cranial Sxs (<0.0001); but not higher mortality https://t.co/qyUpepmryA https://t.co/MJ9kAKl62r

With the FDA's approval of its 50th biosimilar - they have published "A Milestone in Facilitating the Development of Safe and Effective Biosimilars". Since biosimialrs were approved in 2015, they saved the health care system $23.6 billion. https://t.co/7GPJ5XLGnr https://t.co/6Qw7DttmjT